FLT3 Gene

• The FLT3 gene encodes a receptor tyrosine kinase essential for normal blood cell development.
• It regulates the proliferation, differentiation, and survival of hematopoietic stem cells.
• Mutations in the FLT3 gene are common in acute myeloid leukemia (AML) and contribute to uncontrolled cell growth.
• These mutations, particularly FLT3-ITD, are associated with a more aggressive form of AML and a poorer prognosis.
• Targeted therapies are available to inhibit mutated FLT3, improving treatment outcomes for AML patients.

What is the FLT3 Gene?

The FLT3 Gene (FMS-like tyrosine kinase 3 gene) is a gene that provides instructions for making a protein called FMS-like tyrosine kinase 3. This protein is a type of receptor tyrosine kinase, which are cell-surface receptors that play a critical role in cell communication and growth. Located primarily on the surface of hematopoietic stem and progenitor cells, FLT3 acts as a receptor for a specific growth factor, FLT3 ligand, initiating signaling pathways crucial for the normal development of various blood cell types, including white blood cells.

Function and Role of FLT3 in Cellular Processes

The FLT3 gene function and role are central to the intricate processes of hematopoiesis, which is the formation of blood cellular components. When the FLT3 ligand binds to the FLT3 receptor, it triggers a cascade of intracellular signaling events. These pathways are essential for the regulated growth, survival, and differentiation of hematopoietic stem cells into mature blood cells. Without proper FLT3 signaling, the body’s ability to produce a healthy and balanced supply of blood cells would be severely compromised. Key cellular processes influenced by FLT3 include:

• Cell Proliferation: Promoting the division and multiplication of hematopoietic progenitor cells.
• Cell Differentiation: Guiding immature cells to develop into specific mature blood cell types.
• Cell Survival: Preventing programmed cell death (apoptosis) in developing blood cells, ensuring their longevity.

This tightly regulated system ensures a continuous supply of functional blood cells, which are vital for immunity, oxygen transport, and clotting.

FLT3 Gene Mutations and Acute Myeloid Leukemia

Mutations in the FLT3 gene are among the most frequent genetic alterations found in acute myeloid leukemia (AML), an aggressive cancer of the blood and bone marrow. These mutations lead to the FLT3 receptor being constantly active, even without the presence of its ligand, resulting in uncontrolled cell proliferation and impaired differentiation. This dysregulation is a major driver of leukemogenesis.

The most common type of FLT3 mutation is the internal tandem duplication (FLT3-ITD), where a segment of the gene is duplicated and inserted into the same gene. Another significant mutation is the tyrosine kinase domain (FLT3-TKD) point mutation. FLT3-ITD mutations are found in approximately 25-30% of adult AML cases, while FLT3-TKD mutations occur in about 5-10% of cases (Source: National Cancer Institute). Patients with FLT3-ITD mutations often have a higher white blood cell count, a greater risk of relapse, and a generally poorer prognosis compared to those without the mutation.

The clinical manifestations associated with FLT3 gene mutation symptoms are primarily those of acute myeloid leukemia itself. These can include fatigue, shortness of breath, easy bruising or bleeding, recurrent infections, and fever, all stemming from the bone marrow’s inability to produce healthy blood cells. The presence of FLT3 gene and acute myeloid leukemia mutations has significant implications for treatment. Due to the aggressive nature and poor prognosis associated with these mutations, targeted therapies known as FLT3 inhibitors have been developed. These drugs specifically block the activity of the mutated FLT3 receptor, offering a crucial treatment option for patients with FLT3-mutated AML, either alone or in combination with chemotherapy.